QuickView for parC;jsessionid=ECC51C810F3D6B4326F31276183814AE;jsessionid=8FF337EFCF86AD695963068565402983;jsessionid=F7D40E02DB574F7E16FA44FAB64AAAF0;jsessionid=D4CFE27B2B4CFE24D090C72229D6B2E1;jsessionid=763FB08C975D7F62B45CE02C925DD87F;jsessionid=5AFDC106FE1A35E7C507D835D042EB2F;jsessionid=C831F821444EB2E90885E213A5224E2A;jsessionid=36BDD4FDC9B800D2FDE3A0A9486F7179;jsessionid=DA1736D4CFA9C31085CD00035D55A59D;jsessionid=29EEA83DEA1905BC804BD6CAA01D512F (gene)

1. A proteomics approach for the identification of cullin-9 (CUL9) related signaling pathways in induce…
2. Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
3. Cytoplasmic E3 ubiquitin ligase CUL9 controls cell proliferation, senescence, apoptosis and genome i…
4. Killing the Killer: PARC/CUL9 promotes cell survival by destroying cytochrome C.
5. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrit…

There were no clinical trials for parC;jsessionid=ECC51C810F3D6B4326F31276183814AE;jsessionid=8FF337EFCF86AD695963068565402983;jsessionid=F7D40E02DB574F7E16FA44FAB64AAAF0;jsessionid=D4CFE27B2B4CFE24D090C72229D6B2E1;jsessionid=763FB08C975D7F62B45CE02C925DD87F;jsessionid=5AFDC106FE1A35E7C507D835D042EB2F;jsessionid=C831F821444EB2E90885E213A5224E2A;jsessionid=36BDD4FDC9B800D2FDE3A0A9486F7179;jsessionid=DA1736D4CFA9C31085CD00035D55A59D;jsessionid=29EEA83DEA1905BC804BD6CAA01D512F